{"id":"https://openalex.org/W2007268715","doi":"https://doi.org/10.1097/00001813-199205000-00007","title":"Prospective, randomized trial to evaluate high-versus low-dose interferon-\u03b12b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder","display_name":"Prospective, randomized trial to evaluate high-versus low-dose interferon-\u03b12b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder","publication_year":1992,"publication_date":"1992-05-01","ids":{"openalex":"https://openalex.org/W2007268715","doi":"https://doi.org/10.1097/00001813-199205000-00007","mag":"2007268715","pmid":"https://pubmed.ncbi.nlm.nih.gov/1611114"},"language":"en","primary_location":{"id":"doi:10.1097/00001813-199205000-00007","doi":"https://doi.org/10.1097/00001813-199205000-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-199205000-00007","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089347886","display_name":"Wolfgang Hoeltl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111069","display_name":"Krankenanstalt Rudolfstiftung der Stadt Wien","ror":"https://ror.org/019myg640","country_code":"AT","type":"healthcare","lineage":["https://openalex.org/I4210111069","https://openalex.org/I4210117134"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"W Hoeltl","raw_affiliation_strings":["Department of Urology, Krankenanstalt Rudolfstiftung, Vienna, Austria","The authors are at the Department of Urology, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Krankenanstalt Rudolfstiftung, Vienna, Austria","institution_ids":["https://openalex.org/I4210111069"]},{"raw_affiliation_string":"The authors are at the Department of Urology, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Vienna, Austria","institution_ids":["https://openalex.org/I4210111069"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070110142","display_name":"Rudolf Hasun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111069","display_name":"Krankenanstalt Rudolfstiftung der Stadt Wien","ror":"https://ror.org/019myg640","country_code":"AT","type":"healthcare","lineage":["https://openalex.org/I4210111069","https://openalex.org/I4210117134"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"R Hasun","raw_affiliation_strings":["The authors are at the Department of Urology, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The authors are at the Department of Urology, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Vienna, Austria","institution_ids":["https://openalex.org/I4210111069"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109922322","display_name":"W. Albrecht","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111069","display_name":"Krankenanstalt Rudolfstiftung der Stadt Wien","ror":"https://ror.org/019myg640","country_code":"AT","type":"healthcare","lineage":["https://openalex.org/I4210111069","https://openalex.org/I4210117134"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"W Albrecht","raw_affiliation_strings":["The authors are at the Department of Urology, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The authors are at the Department of Urology, Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Vienna, Austria","institution_ids":["https://openalex.org/I4210111069"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210111069"],"apc_list":null,"apc_paid":null,"fwci":1.2403,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.75774064,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":null,"first_page":"29","last_page":"32"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12695","display_name":"Urinary and Genital Oncology Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-alpha-2b","display_name":"interferon alfa-2b","score":0.925000011920929},{"id":"https://openalex.org/keywords/superficial-bladder-cancer","display_name":"superficial bladder cancer","score":0.9330000281333923},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.9750000238418579},{"id":"https://openalex.org/keywords/recurrence-prevention","display_name":"recurrence prevention","score":0.7570000290870667},{"id":"https://openalex.org/keywords/high-dose-interferon","display_name":"high-dose interferon","score":0.7749999761581421},{"id":"https://openalex.org/keywords/low-dose-interferon","display_name":"low-dose interferon","score":0.8859999775886536},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.47999998927116394},{"id":"https://openalex.org/keywords/time-to-recurrence","display_name":"time to recurrence","score":0.5559999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8734817504882812},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6786916255950928},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.651090145111084},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.6430025100708008},{"id":"https://openalex.org/C2778065480","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Transitional cell carcinoma","level":4,"score":0.6018186807632446},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.554925799369812},{"id":"https://openalex.org/C2779762690","wikidata":"https://www.wikidata.org/wiki/Q9382","display_name":"Urinary bladder","level":2,"score":0.5031456351280212},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.47476816177368164},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.46001100540161133},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.4168121814727783},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.4159906208515167},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.41219785809516907},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4069119393825531},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.32100045680999756},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.25209176540374756}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D002295","descriptor_name":"Carcinoma, Transitional Cell","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005009","descriptor_name":"Ethoglucid","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005009","descriptor_name":"Ethoglucid","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/00001813-199205000-00007","doi":"https://doi.org/10.1097/00001813-199205000-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-199205000-00007","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:1611114","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/1611114","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2005723616","https://openalex.org/W2052275620","https://openalex.org/W1958532859","https://openalex.org/W2406558192","https://openalex.org/W1589685447","https://openalex.org/W1514912347","https://openalex.org/W2411135759","https://openalex.org/W2019707035","https://openalex.org/W2099328691","https://openalex.org/W2024597836"],"abstract_inverted_index":{"Forty-four":[0],"patients":[1,48,82],"with":[2,97],"superficial":[3],"bladder":[4,32],"cancer":[5],"were":[6],"randomized":[7],"to":[8,61,88],"receive":[9],"10":[10,36],"MU":[11,16],"(14":[12,17],"patients)":[13,18,28],"or":[14,23],"100":[15],"of":[19,53,73],"interferon":[20],"(IFN)-alpha":[21],"2b":[22,99],"1.3":[24],"g":[25],"ethoglucid":[26,85],"(16":[27],"instilled":[29],"into":[30],"the":[31,51,67],"once":[33],"weekly":[34],"for":[35,41],"weeks":[37],"and":[38,59],"then":[39],"monthly":[40],"1":[42],"year.":[43],"Efficacy":[44],"(evaluated":[45],"in":[46,66,80],"34":[47],"who":[49,83],"completed":[50],"course":[52],"treatment),":[54,90],"based":[55],"on":[56],"recurrence":[57],"rate":[58],"time":[60],"first":[62],"recurrence,":[63],"was":[64,75,95],"similar":[65],"three":[68],"groups.":[69],"No":[70],"systemic":[71],"toxicity":[72,94],"treatment":[74],"seen.":[76],"Severe":[77],"chemocystitis":[78],"occurred":[79],"some":[81],"received":[84],"(three":[86],"had":[87],"discontinue":[89],"while":[91],"no":[92],"local":[93],"seen":[96],"IFN-alpha":[98],"treatment.":[100]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}